MCID: NSP012
MIFTS: 71

Nasopharyngeal Carcinoma

Categories: Rare diseases, Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 53 12 72 49 55 28 51 69
Nasopharyngeal Cancer 53 49 36
Malignant Neoplasm of Nasopharynx 12 69
Nasopharyngeal Carcinoma 1 53 13
Nasopharyngeal Neoplasms 41 69
Nasopharynx Carcinoma 12 14
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx Nos 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Malignant Neoplasm of Nasopharyngeal Wall Nos 12
Malignant Neoplasm of Nasopharynx [ambiguous] 12
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Carcinoma of Nasopharynx 12
Cancer of Nasopharynx 69
Nasopharynx Cancer 12
Npca 53
Npc 53

Characteristics:

Orphanet epidemiological data:

55
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

31
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 55  
Rare respiratory diseases


External Ids:

OMIM 53 607107
Disease Ontology 12 DOID:9261
MeSH 41 D009303
NCIt 46 C9321
Orphanet 55 ORPHA150
MESH via Orphanet 42 C538339
UMLS via Orphanet 70 C2931822 C0153392 C0238301
ICD10 via Orphanet 33 C11.0 C11.1 C11.2 more
MedGen 39 C2931822
KEGG 36 H00054
SNOMED-CT via HPO 65 126680004

Summaries for Nasopharyngeal Carcinoma

OMIM : 53 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

MalaCards based summary : Nasopharyngeal Carcinoma, also known as nasopharyngeal cancer, is related to squamous cell carcinoma and adenocarcinoma, and has symptoms including neoplasia of the nasopharynx, headache and tinnitus. An important gene associated with Nasopharyngeal Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Cisplatin and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and liver, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 72 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.0 CDH1 CDKN2A EGFR HRAS NME1 TP53
2 adenocarcinoma 30.8 CDH1 CDKN2A EGFR HRAS MST1R TP53
3 in situ carcinoma 30.7 CDH1 CDKN2A EGFR TP53
4 cervical adenocarcinoma 30.7 CDKN2A EGFR RASSF1 TP53
5 tongue squamous cell carcinoma 30.7 CASP3 CDH1 CDKN2A TP53
6 tongue cancer 30.6 CDH1 CDKN2A TP53
7 esophageal cancer 30.5 CASP3 CDH1 CDKN2A EGFR HRAS TP53
8 squamous cell carcinoma, head and neck 30.5 CASP3 CDH1 CDKN2A EGFR HRAS RASSF1
9 epstein-barr virus-associated gastric carcinoma 30.4 CDH1 CDKN2A PSMB9
10 keratinizing squamous cell carcinoma 30.3 CDKN2A TP53
11 lung cancer 30.2 BPIFA1 CASP3 CDH1 CDKN2A CYP2E1 EGFR
12 nasopharyngeal carcinoma 3 12.4
13 nasopharyngeal carcinoma 2 12.4
14 nasopharyngeal cancer, childhood 12.0
15 niemann-pick disease, type c1 11.7
16 lymphoepithelioma-like carcinoma 11.4
17 nasopharyngitis 11.2
18 niemann-pick disease, type c2 10.9
19 squamous cell carcinoma of the larynx 10.9 CDKN2A EGFR TP53
20 pre-malignant neoplasm 10.9 CDH1 CDKN2A EGFR TP53
21 oropharynx cancer 10.8 CDKN2A EGFR TP53
22 anal squamous cell carcinoma 10.8 CDKN2A RASSF1 TP53
23 basaloid squamous cell carcinoma 10.8 CDKN2A EGFR TP53
24 breast metaplastic carcinoma 10.8 CDH1 EGFR TP53
25 cholecystitis 10.8 CDH1 CDKN2A RASSF1 TP53
26 vulva cancer 10.8 CDKN2A EGFR TP53
27 mucinous adenocarcinoma 10.8 CDKN2A EGFR TP53
28 brain stem astrocytic neoplasm 10.8 CDKN2A TP53
29 papillary adenocarcinoma 10.8 CDH1 MST1R NME1
30 brain ependymoma 10.8 EGFR TP53
31 spitz nevus 10.8 CDKN2A HRAS TP53
32 cervical squamous cell carcinoma 10.8 CDH1 CDKN2A EGFR RASSF1 TP53
33 gallbladder cancer 10.8 CDH1 CDKN2A EGFR NME1 TP53
34 breast ductal carcinoma 10.8 CDH1 EGFR NME1 TP53
35 grade iii astrocytoma 10.8 CDKN2A EGFR TP53
36 geographic tongue 10.8 EGFR HLA-A NME1
37 nasal cavity adenocarcinoma 10.8 CDKN2A HRAS TP53
38 oral cancer 10.8 CASP3 CDH1 CDKN2A EGFR TP53
39 larynx cancer 10.8 CDKN2A EGFR NME1 TP53
40 reproductive organ cancer 10.8 CASP3 CDH1 CDKN2A EGFR TP53
41 meningeal melanomatosis 10.8 CDKN2A HRAS TP53
42 gastrointestinal system benign neoplasm 10.8 CDH1 CDKN2A HRAS TP53
43 penile cancer 10.8 CDKN2A EGFR HRAS TP53
44 skin melanoma 10.8 CASP3 CDKN2A NME1 TP53
45 biliary tract neoplasm 10.8 CDKN2A HRAS TP53
46 clear cell renal cell carcinoma 10.8 EGFR RASSF1 TP53
47 uterine carcinosarcoma 10.8 EGFR HRAS TP53
48 ductal carcinoma in situ 10.8 CDH1 EGFR TP53
49 colorectal adenocarcinoma 10.8 CDH1 EGFR HRAS TP53
50 endometrial adenocarcinoma 10.8 CDKN2A EGFR TP53

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Clinical features from OMIM:

607107

Human phenotypes related to Nasopharyngeal Carcinoma:

31
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 31 HP:0100630

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, tinnitus, rhinorrhea

GenomeRNAi Phenotypes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.5 EGFR HRAS
2 Decreased viability GR00221-A-1 9.5 CDH1 CDKN2A EGFR HRAS MST1R
3 Decreased viability GR00221-A-2 9.5 HRAS MST1R
4 Decreased viability GR00221-A-3 9.5 CDKN2A HRAS
5 Decreased viability GR00221-A-4 9.5 CDKN2A EGFR
6 Decreased viability GR00301-A 9.5 CDH1 MST1R

MGI Mouse Phenotypes related to Nasopharyngeal Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.11 NME1 NPC1 RASSF1 TP53 CASP3 CDH1
2 immune system MP:0005387 10.06 BPIFA1 CASP3 CDH1 CDKN2A EGFR MST1R
3 integument MP:0010771 9.86 NFKBIA NME1 TP53 CASP3 CDH1 CDKN2A
4 liver/biliary system MP:0005370 9.76 CDKN2A CYP2E1 EGFR MST1R NME1 NPC1
5 neoplasm MP:0002006 9.61 CDH1 CDKN2A CYP2E1 EGFR HRAS NME1
6 no phenotypic analysis MP:0003012 9.17 CASP3 CDH1 CDKN2A EGFR HRAS NPC1

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
3
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
4
Nicotine Approved Phase 4 54-11-5 89594 942
5
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
6 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
11 Autonomic Agents Phase 4,Phase 3,Phase 2
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antidepressive Agents Phase 4,Phase 3,Phase 2
14 Antidepressive Agents, Second-Generation Phase 4,Phase 2
15 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
16 Dopamine Agents Phase 4,Phase 2
17 Dopamine Uptake Inhibitors Phase 4,Phase 2
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
19 Central Nervous System Stimulants Phase 4,Phase 3
20 Cholinergic Agents Phase 4,Phase 3,Phase 2
21 Nicotinic Agonists Phase 4
22
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
23
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
24
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
25
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
26
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
27
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
28
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
29 Racepinephrine Approved Phase 3,Phase 2 329-65-7
30
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
31
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
33
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
34
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
35
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
36
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
39
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
40
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
41
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
42
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
43
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
44
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
45
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
46
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
47
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
49
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
50
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 6918365 151165

Interventional clinical trials:

(show top 50) (show all 543)

# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
3 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
6 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Recruiting NCT03069820 Phase 4 docetaxel and cisplatin
7 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
8 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
9 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
10 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
11 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
12 Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma Unknown status NCT02089204 Phase 2, Phase 3
13 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
14 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
15 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
16 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
17 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
18 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
19 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCIN Unknown status NCT00180973 Phase 3 Hydroxyurea
20 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
21 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
22 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
23 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
24 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
25 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
26 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
27 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
28 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
29 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
30 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
31 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
32 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
33 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
34 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
35 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
36 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
37 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
38 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
39 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
40 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
41 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
42 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
43 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
44 Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma Recruiting NCT03321539 Phase 3 CCRT+GP;CCRT+PF
45 TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Recruiting NCT03306121 Phase 3 TPF+CCRT;CCRT+ PF
46 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
47 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT02958111 Phase 3 Capecitabine
48 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine
49 Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma Recruiting NCT02111460 Phase 3
50 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Recruiting NCT01817023 Phase 3 Cisplatin

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 28 TP53

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

38
Lung, Skin, Liver, Lymph Node, Brain, Breast, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Nasopharyngeal Carcinoma:

18
The Nasopharynx

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 1648)
# Title Authors Year
1
Baicalin hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome instability and splicing. ( 29416665 )
2018
2
Endoscopic Surgery for Delayed Sinonasal Complications of Radiation Therapy for Nasopharyngeal Carcinoma: A Subjective Outcome. ( 29439883 )
2018
3
Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma. ( 29425953 )
2018
4
Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. ( 29451951 )
2018
5
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. ( 28857155 )
2018
6
Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. ( 29445147 )
2018
7
Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update. ( 29413761 )
2018
8
Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. ( 29413276 )
2018
9
Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. ( 29431618 )
2018
10
LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. ( 28987345 )
2018
11
Reduced QSOX1 enhances radioresistance in nasopharyngeal carcinoma. ( 29423042 )
2018
12
Early evaluation of radiation-induced parotid damage in patients with nasopharyngeal carcinoma by T2 mapping and mDIXON Quant imaging: initial findings. ( 29422068 )
2018
13
Functions and Roles of Long-Non-Coding RNAs in Human Nasopharyngeal Carcinoma. ( 29448252 )
2018
14
miR-93 enhances cell proliferation by directly targeting CDKN1A in nasopharyngeal carcinoma. ( 29434867 )
2018
15
Regulatory role of CDX2 and NOX4 expression associated with recurrent nasopharyngeal carcinoma. ( 29424902 )
2018
16
Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma. ( 29416735 )
2018
17
Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. ( 29413277 )
2018
18
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. ( 29428165 )
2018
19
MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. ( 29427737 )
2018
20
Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy. ( 29439312 )
2018
21
Long non-coding RNA LOC100129148 functions as an oncogene in human nasopharyngeal carcinoma by targeting miR-539-5p. ( 28328537 )
2017
22
miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma. ( 28053597 )
2017
23
Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis. ( 28939081 )
2017
24
Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells. ( 28496336 )
2017
25
Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma: A network meta-analysis. ( 28952220 )
2017
26
Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. ( 27923823 )
2017
27
Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: a case-control study. ( 28063457 )
2017
28
2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-I_B/HIF-1 signaling pathway inactivation and EMT reversal. ( 28000883 )
2017
29
Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma. ( 28939083 )
2017
30
Prognostic value of cervical nodal tumor volume in nasopharyngeal carcinoma: Analysis of 1230 patients with positive cervical nodal metastasis. ( 28489930 )
2017
31
Long-Term Progression of Sensorineural Hearing Loss and Tinnitus after Combined Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma: A Case Report. ( 28878660 )
2017
32
FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition. ( 28157708 )
2017
33
Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy. ( 28931426 )
2017
34
Real-time In vivo Diagnosis of Nasopharyngeal Carcinoma Using Rapid Fiber-Optic Raman Spectroscopy. ( 28912892 )
2017
35
CYP2E1 polymorphisms and nasopharyngeal carcinoma risk: a meta-analysis. ( 27491320 )
2017
36
ZNRF3 Inhibits the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma Cells by Inactivating the Wnt/I^-Catenin Pathway. ( 27733215 )
2017
37
The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. ( 28277541 )
2017
38
Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. ( 28467811 )
2017
39
BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma. ( 28083995 )
2017
40
Inactivation of HMGCL promotes proliferation and metastasis of nasopharyngeal carcinoma by suppressing oxidative stress. ( 28931870 )
2017
41
Minicircle-oriP-miR-31 as a Novel EBNA1-specific miRNA Therapy Approach for Nasopharyngeal Carcinoma. ( 28042945 )
2017
42
Oleuropein enhances radiation sensitivity of nasopharyngeal carcinoma by downregulating PDRG1 through HIF1I+-repressed microRNA-519d. ( 28057028 )
2017
43
Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. ( 29095251 )
2017
44
Downregulated ECRG4 is correlated with lymph node metastasis and predicts poor outcome for nasopharyngeal carcinoma patients. ( 27119734 )
2017
45
Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma. ( 28515352 )
2017
46
MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. ( 28931826 )
2017
47
Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study. ( 28532605 )
2017
48
EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma. ( 28347228 )
2017
49
The long noncoding RNA FOXCUT promotes proliferation and migration by targeting FOXC1 in nasopharyngeal carcinoma. ( 28635400 )
2017
50
Late toxicity, evolving radiotherapy techniques, and quality of life in nasopharyngeal carcinoma. ( 28070838 )
2017

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
3 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
4 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
6 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
7 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
8 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
9 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
10 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
11 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
12 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
13 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
14 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
15 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
17 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 605)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 17
2 COSM4995216 ZC3H13 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 17
3 COSM4995307 ZBTB17 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 17
4 COSM4995092 VPS33A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 17
5 COSM4996600 VNN2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 17
6 COSM4995249 VANGL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 17
7 COSM4996245 USP34 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 17
8 COSM4997193 USP19 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 17
9 COSM4995369 USH2A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 17
10 COSM2978223 USH1G upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.520G>A p.D174N 17
11 COSM4995852 USE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 17
12 COSM4996719 TTBK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 17
13 COSM4997149 TSR2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.187G>C p.D63H 17
14 COSM4995873 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 17
15 COSM1524842 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 17
16 COSM4995721 TRAF4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 17
17 COSM2123037 TPR upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3879G>A p.M1293I 17
18 COSM4996315 TP63 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 17
19 COSM10654 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.637C>T p.R213* 17
20 COSM10724 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 17
21 COSM43906 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 17
22 COSM1739496 TNKS upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.583G>A p.V195M 17
23 COSM4996454 TMPRSS11E upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.268G>T p.A90S 17
24 COSM4996730 TFAP2D upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.767C>A p.A256E 17
25 COSM4996391 TET2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4250T>G p.V1417G 17
26 COSM4996386 TET2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.988G>C p.E330Q 17
27 COSM4996526 SYNPO upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1394C>A p.P465Q 17
28 COSM4996648 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.6506C>T p.T2169I 17
29 COSM4996618 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.21845G>C p.W7282S 17
30 COSM4996643 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.7996C>A p.Q2666K 17
31 COSM4996638 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.8339T>C p.L2780P 17
32 COSM4996653 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5827G>A p.E1943K 17
33 COSM4996628 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.14707G>T p.V4903L 17
34 COSM191830 SPTBN1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1916G>A p.R639H 17
35 COSM4995726 SPACA3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.376A>G p.N126D 17
36 COSM4994835 SORCS3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3082G>A p.V1028I 17
37 COSM4995636 SMG1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1682A>G p.Y561C 17
38 COSM2128623 SMG1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2699A>G p.N900S 17
39 COSM4996349 SMARCC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2927G>C p.G976A 17
40 COSM4997191 SLITRK3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.796C>T p.H266Y 17
41 COSM4996929 SLC7A2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.296C>A p.A99E 17
42 COSM4996458 SLC4A4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.331C>G p.L111V 17
43 COSM4997189 SLC19A1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.758G>T p.R253L 17
44 COSM4994897 SIRT1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.568C>A p.Q190K 17
45 COSM4995400 SIPA1L2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2574C>A p.H858Q 17
46 COSM2167722 SF3A3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1081G>A p.E361K 17
47 COSM4996346 SETD2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3808C>T p.R1270C 17
48 COSM4996834 SDK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.6347T>G p.L2116R 17
49 COSM971349 SALL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2582C>T p.S861L 17
50 COSM1332064 S1PR1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.424C>T p.R142C 17

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 CASP3 CDH1 HRAS NFKBIA PSMB9 TP53
2
Show member pathways
12.85 CASP3 CDH1 CDKN2A EGFR HRAS NFKBIA
3
Show member pathways
12.76 CASP3 CDKN2A HRAS NFKBIA TP53
4
Show member pathways
12.71 CDH1 CDKN2A EGFR HRAS TP53
5
Show member pathways
12.68 EGFR HRAS NFKBIA PSMB9 TP53
6
Show member pathways
12.65 CASP3 CDH1 HRAS NFKBIA TP53
7
Show member pathways
12.59 CASP3 EGFR HRAS NFKBIA TP53
8
Show member pathways
12.48 CDKN2A EGFR HRAS NFKBIA TP53
9
Show member pathways
12.46 CASP3 HLA-A HRAS NFKBIA TP53
10 12.36 CASP3 CDKN2A EGFR HRAS RASSF1 TP53
11
Show member pathways
12.34 CASP3 EGFR HRAS NFKBIA TP53
12 12.3 CDKN2A HLA-A HRAS NFKBIA TP53
13
Show member pathways
12.28 CASP3 CDH1 EGFR HRAS NFKBIA TP53
14 12.28 CASP3 CDH1 CDKN2A EGFR HRAS NFKBIA
15 12.24 CASP3 EGFR HRAS TP53
16
Show member pathways
12.21 CASP3 HRAS NFKBIA TP53
17 12.12 CASP3 CDH1 EGFR TP53
18 12.1 CDKN2A HLA-A HRAS TP53
19 12.06 CASP3 CDH1 EGFR TP53
20
Show member pathways
12.02 CDKN2A EGFR HRAS NFKBIA TP53
21
Show member pathways
11.96 CASP3 EGFR HRAS TP53
22 11.95 EGFR HRAS NFKBIA TP53
23 11.94 CASP3 CDKN2A HLA-A HRAS NFKBIA TP53
24 11.86 CDKN2A EGFR HRAS TP53
25 11.8 CASP3 NFKBIA TP53
26 11.68 CASP3 CDKN2A TP53
27 11.63 CASP3 EGFR NFKBIA
28 11.61 EGFR HRAS TP53
29 11.59 CASP3 EGFR HRAS NFKBIA
30 11.49 CDKN2A EGFR TP53
31 11.05 CDH1 EGFR HRAS MST1R
32 10.96 CDH1 CDKN2A EGFR HRAS RASSF1 TP53
33 10.78 CASP3 EGFR HRAS

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.8 HLA-A NFKBIA NPC1 PSMB9 TP53
2 wound healing GO:0042060 9.63 CASP3 EGFR TP53
3 cellular response to drug GO:0035690 9.54 EGFR NME1 TP53
4 positive regulation of epithelial cell proliferation GO:0050679 9.5 EGFR HRAS NME1
5 cell cycle arrest GO:0007050 9.46 CDKN2A HRAS RASSF1 TP53
6 replicative senescence GO:0090399 9.43 CDKN2A TP53
7 positive regulation of MAP kinase activity GO:0043406 9.43 EGFR HRAS MST1R
8 Ras protein signal transduction GO:0007265 9.26 CDKN2A HRAS RASSF1 TP53
9 response to drug GO:0042493 9.1 CASP3 CDH1 CYP2E1 NME1 NPC1 TP53

Molecular functions related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 BPIFA1 CASP3 CDH1 CDKN2A EGFR HLA-A
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CASP3 CDKN2A
3 enzyme binding GO:0019899 9.1 CYP2E1 EGFR MST1R NFKBIA NME1 TP53

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....